Baseline characteristics for all patients enrolled in the study
| Characteristic . | Value . |
|---|---|
| Median age, y | 61 (52-75) |
| Median prior therapies | 0 (0-2) |
| No prior therapy | 27 (63%) |
| Median bone marrow involvement | 55% (5%-100%) |
| Adenopathy and/or splenomegaly | 5 (12%) |
| Median IgM, mg/dL | 3840 (655-10500) |
| IgM > 3000 mg/dL | 27 (63%) |
| Hematocrit < 30% | 15 (35%) |
| Platelets < 100 000/mm3 | 4 (9%) |
| Characteristic . | Value . |
|---|---|
| Median age, y | 61 (52-75) |
| Median prior therapies | 0 (0-2) |
| No prior therapy | 27 (63%) |
| Median bone marrow involvement | 55% (5%-100%) |
| Adenopathy and/or splenomegaly | 5 (12%) |
| Median IgM, mg/dL | 3840 (655-10500) |
| IgM > 3000 mg/dL | 27 (63%) |
| Hematocrit < 30% | 15 (35%) |
| Platelets < 100 000/mm3 | 4 (9%) |